Who are nab-paclitaxel; gemcitabine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Paclitaxel + Gemcitabine admixture.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/nab-paclitaxel-gemcitabine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

nab-paclitaxel; gemcitabine — Competitive Intelligence Brief

nab-paclitaxel; gemcitabine (nab-paclitaxel; gemcitabine) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Chemotherapy combination (taxane + nucleoside analog). Area: Oncology.

phase 3 Chemotherapy combination (taxane + nucleoside analog) Microtubules (paclitaxel); ribonucleotide reductase and DNA (gemcitabine) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

nab-paclitaxel; gemcitabine (nab-paclitaxel; gemcitabine) — Jiangsu HengRui Medicine Co., Ltd.. nab-paclitaxel and gemcitabine work together as a chemotherapy combination to disrupt microtubule dynamics and inhibit DNA synthesis, respectively, to kill rapidly dividing cancer cells.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
nab-paclitaxel; gemcitabine TARGET	nab-paclitaxel; gemcitabine	Jiangsu HengRui Medicine Co., Ltd.	phase 3	Chemotherapy combination (taxane + nucleoside analog)	Microtubules (paclitaxel); ribonucleotide reductase and DNA (gemcitabine)
Paclitaxel + Gemcitabine admixture	Paclitaxel + Gemcitabine admixture	Milton S. Hershey Medical Center	phase 3	Chemotherapy combination (taxane + nucleoside analog)	β-tubulin (paclitaxel); ribonucleotide reductase (gemcitabine)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Chemotherapy combination (taxane + nucleoside analog) class)

Jiangsu HengRui Medicine Co., Ltd. · 1 drug in this class
Milton S. Hershey Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). nab-paclitaxel; gemcitabine — Competitive Intelligence Brief. https://druglandscape.com/ci/nab-paclitaxel-gemcitabine. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab